TrialNeuro-oncology2016

Orally administered colony stimulating factor 1 receptor inhibitor PLX3397 in recurrent glioblastoma: an Ivy Foundation Early Phase Clinical Trials Consortium phase II study.

Nicholas Butowski et al.PubMed ↗Full text ↗Publisher ↗

No numbers read from the abstract.